Between 40 and 60 per cent of people with OCD do not respond to standard treatments — a persistent gap that has driven researchers toward psychedelic-assisted approaches over the past several years.
A single oral dose of psilocybin produced rapid, measurable reductions in obsessive-compulsive disorder symptoms that held for at least 12 weeks, according to the first randomised, placebo-controlled trial testing the compound for OCD. The study was led by Christopher Pittenger at Yale School of Medicine.
The trial enrolled 28 adults who had lived with OCD for an average of two decades and had already failed at least two prior treatments. Participants were scored on a standard symptom scale running from 0 to 40, then randomly assigned to receive either a single oral dose of psilocybin — 0.25 milligrams per kilogram of body weight — or 250 milligrams of niacin, a form of vitamin B3 used as the placebo.
Within 48 hours, symptom scores among the 14 participants who received psilocybin dropped by an average of 9.76 points. Those in the niacin group showed no comparable change. One week out, roughly 70 per cent of the psilocybin group retained a symptom score reduction of around 35 per cent. That improvement was still present at the 12-week follow-up.
What the researchers think is happening
“The speed and durability of the improvement seen after a single dose of psilocybin are remarkable,” said Alex Kwan of Cornell University in Ithaca, New York. The fact that benefits appeared in people who had already exhausted multiple standard options, Kwan says, suggests the compound engages the brain through a different mechanism — though precisely what that mechanism is remains unclear.
Two hypotheses are in play. One holds that psilocybin enhances brain plasticity, loosening the grip of rigid, repetitive thought patterns. David Nutt at Imperial College London, who was not part of this trial, frames it plainly: “If we give you a trip, we think we can break the cycles of obsessive thinking and behaviour.” The other idea, put forward by Pittenger, is that psilocybin recalibrates the relationship between the brain’s default mode network — involved in rumination and self-referential thought — and its other regions.
Nutt, who recently published findings showing that a single dose of the psychedelic DMT reduces depression symptoms, draws a parallel between the two conditions. After a psychedelic experience, he says, “their brain is more flexible and they put them to one side instead of agreeing with them.”
The treatment gap this targets
OCD affects between 1 and 3 per cent of the population. Current options — talking therapies and antidepressants — leave a substantial portion of patients without adequate relief. “It’s definitely better and faster than other medications for OCD,” Nutt said of the psilocybin findings.
Pittenger describes the trip itself as “pretty intense, though it varies from person to person,” a characterisation that points to the practical and regulatory complexity still surrounding any clinical application.
According to the study, the next step is to investigate the biological mechanisms behind psilocybin’s effect on OCD — research that Kwan says could reshape how psychiatry approaches multiple disorders beyond this one condition.
This article is a curated summary based on third-party sources. Source: Read the original article
